For appropriate patients with COPD,
START WITH ANORO INSTEAD OF SPIRIVA HANDIHALER
Explore the head-to-head data for ANORO vs SPIRIVA

A LAMA/LABA vs A LAMA?
On this page:


Studied in patients with moderate or worse COPD (GOLD 2-4).3,4
In a separate study (DB2113374), ANORO ELLIPTA (n=217) compared with SPIRIVA HANDIHALER (n=215) showed a 60‑mL difference* (208 mL and 149 mL, respectively), but due to testing hierarchy, statistical significance cannot be inferred.3
*Reflects rounding.
Patients taking ANORO had fewer rescue albuterol puffs per day over 24 weeks compared with patients taking SPIRIVA3-5


Studied in patients with moderate or worse COPD (GOLD 2-4).3,4
*In DB2113360, LS mean number of rescue albuterol puffs per day over Weeks 1 to 24: ANORO ELLIPTA=2.5, SPIRIVA HANDIHALER=3.2. Difference=0.73,5
In ZEP117115, LS mean number of rescue albuterol puffs per day was 1.8 for ANORO ELLIPTA (n=454) and 2.3 for SPIRIVA HANDIHALER (n=451), which corresponds to a 0.5 difference or a 22% reduction. Other endpoint not adjusted for multiplicity.4,5
In DB2113374, as part of a predefined hierarchy, one comparison for the primary endpoint did not achieve statistical significance, and therefore subsequent comparisons are descriptive only. In this study, the LS mean number of rescue albuterol puffs per day for ANORO ELLIPTA (n=217) and SPIRIVA HANDIHALER (n=215) was 2.9 vs 3.5, respectively.3,5
RANGE OF ADVERSE EVENTS ACROSS THESE STUDIES (%)
ADVERSE EVENTS | ANORO ELLIPTA (n=883) |
SPIRIVA HANDIHALER (n=874) |
Headache | 9-10 | 4-7 |
Nasopharyngitis | 6-10 | 7-8 |
Back pain | 2-5 | 2-5 |
Lower respiratory tract infection | 0-4 | <1-1 |
Upper respiratory tract infection | <1-4 | <1-7 |
COPD* | <1-3 | <1-2 |
Cough | 2-3 | 2-3 |
Gastritis | 0-3 | <1 |
Pain in extremity | <1-3 | <1-2 |
Hypertension | <1-2 | <1-3 |
Urinary tract infection | 0-<1 | <1-3 |
*Signs, symptoms, or progression of COPD are more severe than expected for the subject's condition.
Safety data are descriptive only. The studies were not powered to compare the safety profiles of the products.